A-485 alleviates postmenopausal osteoporosis by activating GLUD1 deacetylation through the SENP1-Sirt3 signal pathway

Abstract Objective Postmenopausal osteoporosis (OP) is a bone disease caused by estrogen deficiency. A-485 is a selective inhibitor of p300/CBP histone acetyltransferase (HAT) with potential regulatory effects on bone remodeling. This study aims to investigate the effects of A-485 on postmenopausal...

Full description

Saved in:
Bibliographic Details
Main Authors: Yinghong Ma, Xiaohua Zou, Qianhong Jian, Jiaxin Dong, Xianbing Huang, Yue Zhai, Li Qian
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Journal of Orthopaedic Surgery and Research
Subjects:
Online Access:https://doi.org/10.1186/s13018-025-05839-4
Tags: Add Tag
No Tags, Be the first to tag this record!